BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
SUNNYVALE, Calif., March 13, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (Nasdaq:BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, and StemCardia, Inc., a biotechnology company focused on cell and gene therapy to re-muscularize the failing heart, today announced a long-term partnership to advance StemCardia’s investigational pluripotent stem cell product candidate for the treatment of heart failure.